Weekly administration of docetaxel for symptomatic metastatic hormone‐refractory prostate carcinoma

Open Access
Publisher Website
Google Scholar
Abstract
BACKGROUND The current Phase II study investigated the clinical benefit, impact on quality of life (QOL), and tolerability of weekly docetaxel in symptomatic patients with metastatic hormone‐refractory prostate carcinoma (HRPC). METHODS Patients received weekly docetaxel 35 mg/m2 intravenously for 6 consecutive weeks followed by a 2‐week rest repeatedly for a maximum of 24 weeks of treatment. Clinical benefit evaluations, based on Karnofsky performance status (KPS) and pain, were assessed weekly during therapy. A clinical benefit response was defined as a sustained (≥ 4‐week) improvement in at least one of these parameters without worsening in the other. Patient‐assessed QOL (using the European Organization for Research and Treatment of Cancer QLQ‐C30), changes in prostate‐specific antigen (PSA) levels, tumoral response, and toxicity also were evaluated. RESULTS Thirty men (median age, 67 years), 15 of whom had received previous chemotherapy, were treated. Overall, 46% of patients achieved a positive pain response and 48% achieved a 50%‐or‐greater reduction in PSA. KPS was high at baseline (80%), and no significant changes in this parameter were observed. Compared with baseline, all scores improved after the first cycle of therapy, particularly emotional (P = 0.015), pain (P = 0.001), constipation (P = 0.001), and global QOL (P = 0.011) scores. After the second cycle, dyspnea scores decreased (P = 0.010). At the last QOL assessment, there also was deterioration in terms of fatigue (P = 0.013), dyspnea (P = 0.010), and physical functioning (P = 0.017). Toxicity was mild and included neutropenia (Grade 3–4, n = 2). CONCLUSIONS Of these elderly symptomatic patients with HRPC, half had received previous chemotherapy. Weekly docetaxel was found to be associated with improvements in clinical benefit response and in QOL and was well tolerated. Cancer 2003. © 2003 American Cancer Society. DOI 10.1002/cncr.11687